`___________________
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`___________________
`MYLAN PHARMACEUTICALS INC., TEVA PHARMACEUTICALS USA,
`INC., WATSON LABORATORIES, INC., DR. REDDY’S LABORATORIES,
`INC., DR. REDDY’S LABORATORIES, LTD., and SUN
`PHARMACEUTICALS INDUSTRIES LTD.1
`Petitioner,
`v.
`MERCK SHARP & DOHME CORP.
`Patent Owner.
`U.S. Patent No. 7,326,708 to Cypes et al.
`Issue Date: February 5, 2008
`Title: Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor
`Inter Partes Review No.: IPR2020-00040
`
`UPDATED EXHIBIT LIST AS OF JANUARY 27, 2021
`
`Mail Stop “PATENT BOARD”
`Patent Trial and Appeal Board
`U.S. Patent and Trademark Office
`P.O. Box 1450
`Alexandria, VA 22313-1450
`
`1 Teva Pharmaceuticals USA, Inc. and Watson Laboratories, Inc. were joined as a party to this proceeding via Motion
`for Joinder in IPR2020- 01045; Dr. Reddy’s Laboratories, Inc. and Dr. Reddy’s Laboratories, Ltd. were joined as a
`party to this proceeding via a Motion for Joinder in IPR2020-01060; and Sun Pharmaceuticals Industries Ltd. was
`joined as a party to this proceeding via Motion for Joinder in IPR2020-01072.
`
`US_146956929v1_391026-00257
`
`
`
`Petitioner
`Exhibit #
`1001
`1002
`1003
`1004
`1005
`1006
`
`1007
`1008
`1009
`1010
`
`1011
`1012
`1013
`1014
`1015
`
`1016
`
`1017
`1018
`1019
`1020
`1021
`1022
`1023
`1024
`1025
`1026
`
`1027
`1028
`1029
`1030
`1031
`
`Description
`U.S. Patent No. 7,326,708
`Declaration of Dr. Mukund Chorghade
`CV of Dr. Mukund Chorghade
`WO 03/004498 to Edmonson
`Brittain, “Polymorphism in Pharmaceutical Solids”
`Bastin et al. “Salt Selection and Optimisation [sic] Procedures for
`Pharmaceutical New Chemical Entities”
`U.S. Patent No. 6,699,871
`Orange Book Entry for Janumet®
`Orange Book Entry for Januvia®
`Complete copy of the prosecution history of the ’708 patent as
`available for download from the USPTO website
`U.S. Patent No. 4,572,909
`U.S. Provisional Application No. 60/303,474, filed July 6, 2001
`Prescribing Information for Janumet®
`Prescribing Information for Januvia®
`Merck Sharpe & Dohme’s Responses and Objections to
`Defendants’ First Set of Joint Interrogatories (1-10)
`Brown et al., Chemistry: The Central Science, 8th Revised Edition
`615-618 (2002)
`Transcript of Telephonic Hearing Of March 4, 2020
`Transcript of Telephonic Hearing Of August 10, 2020
`Affidavit of Robert M. Wenslow, Ph.D. from Israeli Proceedings
`U.S. Patent No. 8,425,659
`Webster’s II, New College Dictionary, 242-243 (2001)
`Deposition of Robert M. Wenslow, Ph.D. of October 22, 2020
`Deposition of Gary Herman, M.D. of October 26, 2020
`Deposition of Karl Hansen, of October 8, 2020
`Deposition of Adam Matzger, Ph.D. of October 30, 2020
`Declaration of Professor Allen S. Myerson, Ph.D. Regarding
`Claim Construction
`Markman Order of August 17, 2020
`Declaration of Liad Whatstein
`Second Declaration of Adam J. Matzger
`Chyall Lab Notebook 4063
`Deposition of Allen S. Myerson, Ph.D. of November 3, 2020
`
`US_146956929v1_391026-00257
`
`
`
`1032
`1033
`1034
`1035
`1036
`
`Deposition of Vicky Vydra of November 10, 2020
`U.S. Patent Application Publication No. 2010/0041885
`Joint Claim Construction Brief
`Reply Declaration of Dr. Mukund Chorghade, Ph.D.
`Declaration of Noam Blei
`
`US_146956929v1_391026-00257
`
`